With its plans for a US launch of its first drug delayed by the FDA, Oxford Glycosciences last week embarked on a reorganization and cost-cutting initiative designed to shore up the company’s short-term finances.
With its plans for a US launch of its first drug delayed by the FDA, Oxford Glycosciences last week embarked on a reorganization and cost-cutting initiative designed to shore up the company’s short-term finances.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.